Press Releases GENFIT

Equities

GNFT

FR0004163111

Real-time Euronext Paris Other stock markets 03:53:34 02/05/2024 pm IST			5-day change	1st Jan Change
3.205 ^EUR	+0.16%		-0.93%	-9.46%

01/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	MT
26/04	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)	26/04	GL
GENFIT : Extra-Financial Performance Report 2024, 2023 Activity	25/04	PU
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents	16/04	GL
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F	05/04	GL
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update	05/04	GL
GENFIT : Corporate presentation - Investor Events - April 2024	04/04	PU
GENFIT Announces Revenues and Cash Position as of December 31, 2023	01/03	GL
GENFIT Announces Revenues and Cash Position as of December 31, 2023	01/03	AQ
GENFIT Announces 2024 Financial Calendar	16/01	GL
GENFIT Announces 2024 Financial Calendar	16/01	AQ
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial	12/01	GL
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)	08/12	GL
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC	07/12	GL
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials	06/12	GL
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials	06/12	AQ
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023	17/11	GL
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023	17/11	AQ
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine	14/11	GL
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine	14/11	AQ
GENFIT : Document AMF CP. 2023E937612	10/11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GENFIT

Equities

GNFT

FR0004163111

Press Releases

Filters